Patents by Inventor Jacques Banchereau
Jacques Banchereau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230374608Abstract: Provided herein, in some embodiments, are methods, compositions, and systems for identifying alternatively spliced tumor-specific exon inclusion and exclusion events that can be used for survival prognosis.Type: ApplicationFiled: April 18, 2023Publication date: November 23, 2023Applicant: The Jackson LaboratoryInventors: Jacques Banchereau, Diogo Fremando Troggian Veiga, Anne Deslattes Mays, Saman Zeeshan, Anna Karolina Palucka
-
Publication number: 20230340524Abstract: The present disclosure provides immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG™) mouse models that comprise an inactivated mouse Flt3 allele and, in some models, additional genetic modifications. These mouse models useful, for example, for superior engraftment of diverse hematopoietic lineages and for immune-oncology, immunology and infectious disease studies.Type: ApplicationFiled: July 7, 2021Publication date: October 26, 2023Applicant: The Jackson LaboratoryInventors: Anna Karolina Palucka, Chun l. Yu, Jacques Banchereau, Richard Maser
-
Publication number: 20230270085Abstract: The present disclosure provides an immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG™) mouse models that comprise an inactivated mouse Flt3 allele, a nucleic acid encoding human interleukin 3 (IL3), a nucleic acid encoding human granulocyte/macrophage-stimulating factor (GM-CSF), a nucleic acid encoding human stem cell factor (SCF), and a HLA-A2/H2-D/B2M transgene encoding (i) a human B2-microglubulin (B2M) covalently linked to MHC class 1, alpha 1, and alpha2 binding domains of a human HLA-A2.1 gene and (ii) alpha3 cytoplasmic and transmembrane domains of murine H2-db.Type: ApplicationFiled: July 7, 2021Publication date: August 31, 2023Applicant: The Jackson LaboratoryInventors: Anna Karolina Palucka, Chu l. Yu, Jacques Banchereau, Richard Maser, Leonard D. Shultz
-
Patent number: 11674187Abstract: Provided herein, in some embodiments, are methods, compositions, and systems for identifying alternatively spliced tumor-specific exon inclusion and exclusion events that can be used for survival prognosis.Type: GrantFiled: June 28, 2019Date of Patent: June 13, 2023Assignee: The Jackson LaboratoryInventors: Jacques Banchereau, Diogo Fernando Troggian Veiga, Anne Deslattes Mays, Saman Zeeshan, Anna Karolina Palucka
-
Publication number: 20210254176Abstract: Provided herein, in some embodiments, are methods, compositions, and systems for identifying alternatively spliced tumor-specific exon inclusion and exclusion events that can be used for survival prognosis.Type: ApplicationFiled: June 28, 2019Publication date: August 19, 2021Applicant: The Jackson LaboratoryInventors: Jacques Banchereau, Diogo Fernando Troggian Veiga, Anne Deslattes Mays, Saman Zeeshan, Anna Karolina Palucka
-
Publication number: 20210233640Abstract: Methods and apparatus for identifying alternative splicing events. The method comprises receiving a dataset of percent spliced in (PSI) values for each of a plurality of biological samples, wherein the plurality of biological samples includes a first population of samples having a first characteristic and a second population of samples having a second characteristic different from the first characteristic, fitting, to the dataset, a probabilistic model to identify clusters of samples in the dataset, calculating cluster characteristics for each of the clusters, filtering the clusters based, at least in part, on the cluster characteristics to identify a subset of clusters, each of which is associated with an alternative splicing event, and storing on the at least one storage device, information associated with the identified alternative splicing events.Type: ApplicationFiled: June 26, 2019Publication date: July 29, 2021Applicant: The Jackson LaboratoryInventors: Jacques Banchereau, Diogo Fernando Troggian Veiga, Anne Deslattes Mays
-
Publication number: 20190082664Abstract: The present disclosure provides, in some aspects, a humanized mouse (NSG™-SGM3), engrafted with CD34+ hematopoietic progenitor cells and human metastatic melanoma cells, which surprisingly promotes secondary metastatic colonization, modeling the interplay between human tumors and the human immune system, and thus enabling mechanistic and pre-clinical studies for the development of novel treatment strategies targeting human-specific molecular pathways controlling melanoma dissemination.Type: ApplicationFiled: September 14, 2018Publication date: March 21, 2019Applicant: The Jackson LaboratoryInventors: Anna Karolina Palucka, Jacques Banchereau, Chun I. Yu
-
Patent number: 9885017Abstract: Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.Type: GrantFiled: January 10, 2014Date of Patent: February 6, 2018Assignees: BAYLOR RESEARCH INSTITUTE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Helene Dutartre, Yves Levy, Jacques Banchereau, Gerard Zurawski
-
Patent number: 9416186Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: GrantFiled: August 26, 2013Date of Patent: August 16, 2016Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
-
Patent number: 9061066Abstract: Cyclic beta glucan compounds function as an immunoadjuvant when administered prior to, concommitantly with, or subsequent to the administration of one or more antigens to a subject. These adjuvant compounds may be effectively used as dendritic cell activating molecules.Type: GrantFiled: June 6, 2011Date of Patent: June 23, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite d'Aix-MarseilleInventors: Jean-Pierre Gorvel, Jacques Banchereau, Anna Martirosyan, Eynav Klechevsky, Sangkon Oh
-
Publication number: 20150166655Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: ApplicationFiled: December 16, 2014Publication date: June 18, 2015Inventors: Jacques BANCHEREAU, Kiley PRILLIMAN, Virginia PASCUAL, Anna Karolina PALUCKA
-
Publication number: 20140199763Abstract: Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.Type: ApplicationFiled: January 10, 2014Publication date: July 17, 2014Applicants: Institut National de la Sante et de la Recherche Medicale ( INSERM), Baylor Research InstituteInventors: Helene Dutartre, Yves Levy, Jacques Banchereau, Gerard Zurawski
-
Publication number: 20140179807Abstract: The present invention includes an apparatus, system and method for the development and use of transcriptional modules by obtaining individual gene expression levels from cells obtained from one or more patients with a disease or condition; recording the expression value for each gene in a table that is divided into clusters; iteratively selecting gene expression values for one or more transcriptional modules by: selecting for the module the genes from each cluster that match in every disease or condition; removing the selected genes from the analysis; and repeating the process of gene expression value selection for genes that cluster in a sub-fraction of the diseases or conditions; and iteratively repeating the generation of modules.Type: ApplicationFiled: October 17, 2013Publication date: June 26, 2014Applicant: Baylor Research InstituteInventors: Damien Chaussabel, Jacques Banchereau
-
Publication number: 20140154239Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: ApplicationFiled: December 5, 2012Publication date: June 5, 2014Inventors: Jacques Banchereau, Kiley Prilliman, Virginia Pascual, Anna Karolina Palucka
-
Publication number: 20140127198Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: ApplicationFiled: August 26, 2013Publication date: May 8, 2014Applicant: Baylor Research InstituteInventors: Gerard Zurawski, Jacques Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
-
Publication number: 20130129756Abstract: The present invention relates to a cyclic beta glucan compound for use as an immuno adjuvant and vaccine composition comprising thereof. These novel adjuvant compounds represent in particular a new class of dendritic cell activating molecules.Type: ApplicationFiled: June 6, 2011Publication date: May 23, 2013Inventors: Jean-Pierre Gorvel, Jacques Banchereau, Anna Martirosyan, Eynav Klechevsky, Sangkon Oh
-
Patent number: 8333965Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: GrantFiled: October 4, 2011Date of Patent: December 18, 2012Assignee: Baylor Research InstituteInventors: Jacques Banchereau, Kiley Prilliman, Virginia Pascual, Anna Karolina Palucka
-
Publication number: 20120258120Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with auto-inflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks IL-1? receptors.Type: ApplicationFiled: June 19, 2012Publication date: October 11, 2012Applicant: BAYLOR RESEARCH INSTITUTEInventors: Jacques Banchereau, Virginia Pascual
-
Publication number: 20120237513Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.Type: ApplicationFiled: April 24, 2012Publication date: September 20, 2012Applicant: BAYLOR RESEARCH INSTITUTEInventors: Gerard Zurawski, Jacques Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
-
Patent number: 8221748Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.Type: GrantFiled: October 13, 2009Date of Patent: July 17, 2012Assignee: Baylor Research InstituteInventors: Jacques Banchereau, Virginia Pascual